Efficiency and tolerance of immunotherapy in the treatment of cancer patients living with HIV

The French CANCERVIH network, coordinated by Prof. Jean-Philippe Spano of the Medical Oncology Department of the Pitié-Salpêtrière Hospital AP-HP and Sorbonne University, studied the efficacy and safety of immunotherapy on the world’s largest series of HIV-infected people with cancer treated in routine care (excluding clinical trials).

The results, which show that the treatment is effective and well tolerated, represent a real advance in the management of HIV-infected patients with cancer.  They were published on 26 June 2019 in the journal AIDS.

More information : https://www.aphp.fr/contenu/efficacite-et-tolerance-de-limmunotherapie-dans-le-traitement-de-patients-atteints-de-cancer

Sources : 

Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience.

Spano JP¹, Veyri M², Gobert A³, Guihot A⁴, Perré P⁵, Kerjouan M⁶, Brosseau S⁷, Cloarec N⁸, Montaudie H⁹, Helissey C¹⁰, Flament T¹¹, Gounant V⁷, Lavolé A¹², Poizot-Martin I¹³, Katlama C¹⁴.

AIDS. 2019 Jun 26. doi: 10.1097/QAD.0000000000002298.